Foghorn Therapeutics Inc

This management proposal requests a non-binding, advisory endorsement of the company’s disclosed executive compensation for fiscal year 2025 (a typical ‘say-on-pay’ vote) to provide shareholders a mechanism to express their approval or disapproval of the overall pay framework and outcomes. Management is seeking this approval to validate its pay practices—which it describes as designed to attract, retain and incentivize management to achieve scientific, clinical and business milestones—and to obtain shareholder feedback that the Compensation Committee will consider when setting future pay. Context includes the company’s transition out of emerging growth company status, making this the first year it holds a say-on-pay vote, and its use of Pay Governance as an independent compensation consultant and a compensation program featuring base salary, annual bonuses tied to corporate performance goals, and multi-year equity option grants. Because the vote is advisory, it does not bind the Board, but the Board and Compensation Committee state they will take the results under advisement and may adjust compensation policies in response to shareholder sentiment. Key governance considerations for an analyst include the pay-for-performance linkages disclosed (annual bonuses tied to specific corporate performance goals and equity vesting schedules), severance and change-in-control protections, clawback policy adoption, and the use of market benchmarking. The company discloses substantial equity-based compensation and post-termination protections that may be viewed positively for retention but raise potential concerns about dilution and change-in-control windfalls; the Compensation Committee notes it will factor the advisory vote into future decisions. Given the company’s stage and recent financing and collaboration activity (notably with Lilly and a 2026 equity offering), executive incentives may be materially influenced by near-term clinical and financing milestones, which bears on how shareholders should evaluate realized versus reported pay. An informed investor-facing analysis should weigh disclosed compensation actually paid versus reported grant-date values, the company’s performance (net losses and TSR disclosures), independence of compensation advisors, and whether the compensation structure balances long-term value creation with prudent governance constraints. Overall, the management recommendation for a FOR vote rests on the Committee’s view that the program is appropriately structured to support corporate objectives while remaining responsive to shareholder feedback.

This management-led, non-binding proposal asks shareholders to indicate their preferred frequency (1, 2, or 3 years) for future advisory votes on executive compensation, with the Board endorsing an annual (1-year) frequency. Management frames an annual vote as the optimal mechanism to allow consistent and meaningful shareholder feedback on pay, particularly now that the company is no longer an emerging growth company and is instituting its first-year say-on-pay. The company notes the vote is advisory and that the Compensation Committee and Board will consider but are not bound by the result; they will also ensure compliance with the statutory minimum (no less frequently than once every three years). For an analyst, key considerations include whether annual voting increases responsiveness to shareholder concerns and governance transparency versus potential short-termism pressures it may place on compensation design, especially given the company’s heavy equity-based incentives and milestone-driven clinical development pathway. The Board’s recommended one-year frequency aligns with a desire for ongoing engagement, which may be sensible for a clinical-stage biopharma where developments are frequent, but it may also invite more frequent scrutiny and pressure to shift pay structures toward shorter-term metrics. The company’s recent financing and collaboration activities increase the materiality of executive incentives, making regular shareholder feedback useful; however, investors should evaluate whether annual votes meaningfully change compensation outcomes or simply generate recurring non-binding advisory results. Overall, the Board’s rationale for annual frequency is credible given the company’s stage, but sophisticated investors should weigh benefits of engagement against the potential for short-term performance incentives and consider how the Compensation Committee might balance annual shareholder input with long-term strategic goals.